
RANI Stock Forecast & Price Target
RANI Analyst Ratings
Bulls say
Rani Therapeutics Holdings Inc. has developed the RaniPill capsule, a proprietary technology that allows for the oral administration of biologics, thus providing a convenient alternative to painful injections. Strong preclinical data reveals that RaniPill demonstrates bioavailability of approximately 111%, equating to systemic exposure comparable to subcutaneous delivery, which supports the advancement of their pipeline toward first-in-human studies in 2025. Furthermore, the company is well-capitalized with a cash runway projected through 2028, positioning it favorably for growth amid increasing interest and M&A activity in the next-generation oral drug delivery market.
Bears say
Rani Therapeutics Holdings Inc faces several challenges that contribute to a negative outlook on its stock. Firstly, there are concerns regarding management turnover, which may disrupt clinical development progress and negatively affect share performance, casting doubt on the company's ability to gain market share in a competitive landscape. Additionally, uncertainties surrounding reimbursement levels and the potential for competing market entrants could adversely impact revenue forecasts and sales of Rani's product offerings, further exacerbating the company's financial vulnerability.
This aggregate rating is based on analysts' research of Rani Therapeutics Holdings and is not a guaranteed prediction by Public.com or investment advice.
RANI Analyst Forecast & Price Prediction
Start investing in RANI
Order type
Buy in
Order amount
Est. shares
0 shares